Mavorixafor Explained
| Tradename: | Xolremdi |
| Dailymedid: | Mavorixafor |
| Routes Of Administration: | By mouth |
| Class: | CXCR4 antagonist |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Cas Number: | 558447-26-0 |
| Pubchem: | 11256587 |
| Iuphar Ligand: | 8580 |
| Drugbank: | DB05501 |
| Chemspiderid: | 9431613 |
| Unii: | 0G9LGB5O2W |
| Kegg: | D11510 |
| Chebi: | 138865 |
| Chembl: | 518924 |
| Synonyms: | X4P-001; AMD-070 |
| Iupac Name: | -(1H-Benzimidazol-2-ylmethyl)--[(8''S'')-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine |
| C: | 21 |
| H: | 27 |
| N: | 5 |
| Smiles: | C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3 |
| Stdinchi: | 1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1 |
| Stdinchikey: | WVLHHLRVNDMIAR-IBGZPJMESA-N |
Mavorixafor, sold under the brand name Xolremdi, is a medication used for the treatment of WHIM syndrome. It is a CXC chemokine receptor 4 antagonist. It is taken by mouth. It was developed by X4 Pharmaceuticals.
The most frequently reported adverse reactions include thrombocytopenia (low platelet counts), rash, rhinitis (stuffy nose), epistaxis (nosebleed), vomiting, and dizziness.
Mavorixafor was approved for medical use in the United States in April 2024.[2] [3] [4]
Medical uses
Mavorixafor is indicated in people twelve years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
Adverse effects
Mavorixafor is expected to cause harm to the baby.
History
The effectiveness of mavorixafor was evaluated in a 52-week, randomized, double-blind, placebo-controlled trial that enrolled 31 adolescents and adults with WHIM syndrome (NCT03995108). Mavorixafor improved absolute neutrophil counts and absolute lymphocyte counts, assessed over a 24-hour period four times throughout the study. Absolute neutrophil counts below 500 cells/μL and absolute lymphocyte counts below 1000 cells/μL are associated with an increased risk of infections. The average length of time over 24 hours that counts were above these levels was significantly longer with mavorixafor compared to the placebo group (15.0 hours compared to 2.8 hours for absolute neutrophil counts; 15.8 hours compared to 4.6 hours for absolute lymphocyte counts).
Society and culture
Names
Mavorixafor is the international nonproprietary name.[5]
Research
Mavorixafor is in clinical trials for melanoma[6] and renal cell carcinoma.[7]
Notes and References
- Web site: Xolremdi- mavorixafor capsule, gelatin coated . DailyMed . 4 June 2024 . 16 June 2024.
- Web site: FDA approves first drug for WHIM syndrome, a rare disorder . U.S. Food and Drug Administration (FDA) . 29 April 2024 . 29 April 2024 . 29 April 2024 . https://web.archive.org/web/20240429222855/https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections . live .
- Web site: Novel Drug Approvals for 2024 . U.S. Food and Drug Administration (FDA) . 29 April 2024 . 30 April 2024 . 30 April 2024 . https://web.archive.org/web/20240430031024/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 . live .
- X4 Pharmaceuticals Announces FDA Approval of Xolremdi (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome . X4 Pharmaceuticals . GlobeNewswire . 29 April 2024 . 29 April 2024 . 29 April 2024 . https://web.archive.org/web/20240429103703/https://www.globenewswire.com/news-release/2024/04/29/2871050/0/en/X4-Pharmaceuticals-Announces-FDA-Approval-of-XOLREMDI-mavorixafor-Capsules-First-Drug-Indicated-in-Patients-with-WHIM-Syndrome.html . live .
- ((World Health Organization)) . 2018 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80 . WHO Drug Information . 32 . 3 . 10665/330907 . free . World Health Organization .
- Andtbacka . Robert H.I. . Wang . Yan . Pierce . Robert H. . Campbell . Jean S. . Yushak . Melinda . Milhem . Mohammed . Ross . Merrick . Niland . Katie . Arbeit . Robert D. . Parasuraman . Sudha . Bickley . Kris . Yeung . Cecilia CS . Aicher . Lauri D. . Smythe . Kimberly S. . Gan . Lu . Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma . Cancer Research Communications . 31 August 2022 . 2 . 8 . 904–913 . 10.1158/2767-9764.CRC-22-0090. free . 36923305 . 10010370 .
- Choueiri . Toni K. . Atkins . Michael B. . Rose . Tracy L. . Alter . Robert S. . Ju . Yawen . Niland . Katie . Wang . Yan . Arbeit . Robert . Parasuraman . Sudha . Gan . Lu . McDermott . David F. . A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy . Investigational New Drugs . August 2021 . 39 . 4 . 1019–1027 . 10.1007/s10637-020-01058-2. 33507454 . 231746027 .
